Pharmaceutical

Nanomerics Wins the United Kingdom King’s Award for Enterprise Innovation 2024

Nanomerics Ltd., a private speciality pharmaceutical company today announced that it had been awarded the prestigious King's Award for Enterprise…

8 months ago

Pushing the Boundaries of Neuroscience with GE HealthCare’s SIGNA MAGNUS

SIGNA MAGNUSi is a high-performance head-only MR scanner from GE HealthCare that could expand the field of neuroscience, which has…

8 months ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights…

8 months ago

Forbes Has Listed Gilead as One of America’s Best Employers for Diversity

NORTHAMPTON, MA / ACCESSWIRE / May 3, 2024 / Gilead SciencesForbes has listed Gilead as one of America's Best Employers…

8 months ago

Humonix Biosciences Appoints Karen Torrejon, PhD, as New Chief Executive Officer

Dr. Torrejon, the original founder of Humonix, replaces Kimberly SouthernALBANY, NY / ACCESSWIRE / May 2, 2024 / Humonix Biosciences,…

8 months ago

Theralase(R) Expands Clinical Team

TORONTO, ON / ACCESSWIRE / May 2, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

8 months ago

Bausch Health Announces First Quarter 2024 Results

First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basisYear-over-year revenue growth in…

8 months ago

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates

Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for…

8 months ago

ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics

New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab…

8 months ago

Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel…

8 months ago